Introduction
Thromboembolic events are considered to be critical complications of nephrotic syndrome. Much evidence suggests that nephrotic syndrome is associated with a hypercoagulable state.
Altered coagulation factor profiles and increased viscosity due to volume depletion may play a role in thrombus formation.
The renal vein and deep vein of the lower limbs are most frequently involved, which often lead to acute kidney injury and pulmonary embolism, respectively. The portal vein, however, is a rare site of thrombus formation in patients with nephrotic syndrome and may be misdiagnosed when physicians assess abdominal pain in these patients. This report describes a case of histologically proven minimal change disease (MCD) complicated by portal vein thrombosis.
Case
A 26-year-old male visited our hospital due to sudden nausea, vomiting, and epigastric pain. Five months before the visit, he was diagnosed with MCD by renal biopsy. Complete remission was achieved after treatment with oral corticosteroids at an initial dose of 1 mg/kg/day, followed by a slow taper over the next four months. Blood pressure was 101/76 mmHg, heart rate 72/min, respiratory rate 16/min, and body temperature 37.4 o C. On physical examination, the abdomen was tense and rigid. There was direct tenderness in the epigastric abdominal area without rebounding tenderness. Pretibial pitting edema and ascites were also noted, but his mouth and tongue were dry. Among the possible venous thromboembolic events in nephrotic syndrome, renal vein thrombosis and pulmonary embolism are common, while portal vein thrombosis (PVT) is rare. This report describes a 26-year-old man with histologically proven minimal change disease (MCD) complicated by PVT. The patient presented with epigastric pain and edema. He had been diagnosed with MCD five months earlier and achieved complete remission with corticosteroids, which were discontinued one month before the visit. Full-blown relapsing nephrotic syndrome was evident on laboratory and clinical findings, and an abdominal computed tomography revealed PVT. He immediately received immunosuppressants and anticoagulation therapy. An eight-week treatment resulted in complete remission, and a follow-up abdominal ultrasonography showed disappearance of PVT. In conclusion, PVT is rare and may not be easily diagnosed in patients with nephrotic syndrome suffering from abdominal pain. Early recognition of this rare complication and prompt immunosuppression and anticoagulation therapy are encouraged to avoid a fatal outcome. Portal Vein Thrombosis in Minimal Change Disease hibitor 1; and impaired thrombolytic activity, such as decreased plasminogen levels [1] [2] [3] [4] . In addition, hypovolemia-induced hyperviscosity, hypercholesterolemia, hypoalbuminemia, and the use of corticosteroid are also associated with the development of thromboembolic events [5] [6] [7] .
Thromboembolic events most commonly involve the renal vein, deep vein of the lower limbs in patients with the greatest risk seen in membranous glomerulopathy, menbranoproliferative glomerulonephritis, and minimal change disease among subtypes of nephrotic syndrome [2, 3] . Portal vein thrombosis is rare.
A review of the literature identified nine cases of portal vein thrombosis to date ( histologically proven by renal biopsy, while the others were clinically presumed to have MCD due to a rapid response to steroid therapy, but renal biopsy was not performed. In line with these findings, our patient clearly had a relapse of MCD and exhibited a markedly hypovolemic status presenting polycythemia (58.6%) before the use of diuretics and full-blown nephrotic Spontaneous recanalization after portal vein thrombosis is unlikely, but recanalization occurs in about 40% of patients treated with anticoagulation therapy, which can prevent further thrombosis and development of portal hypertension and its complications [17, 18] . Timing of the initiation of anticoagulation therapy is important because the probability of recanalization decreases from 69% when anticoagulation is initiated within the first week after diagnosis to 25% when initiated in the second week [18, 19] . Although there is currently no pre-set guideline on anticoagulation therapy in patients with nephrotic syndrome complicated by thromboembolic events, immediate anticoagulation treatment with unfractionated or low molecular heparin and oral warfarin is recommended in symptomatic portal vein thrombosis. Also, anticoagulant therapy should be maintained for the duration of nephrotic syndrome as long as the thromboembolic risk persists [3] . Furthermore, achieving remission of nephrotic syndrome with immunosuppression is of paramount importance to recover the altered coagulation profiles.
In conclusion, portal vein thrombosis is rare and may not be easily diagnosed in patients with nephrotic syndrome suffering from abdominal pain. Early recognition of this rare complication and prompt anticoagulation therapy and immunosuppression are emphasized to avoid a fatal outcome.
